Combining Tamsulosin (Flomax) and Oxybutynin: Safety and Efficacy
Yes, tamsulosin and oxybutynin can be safely combined and this combination is more effective than tamsulosin monotherapy for men with lower urinary tract symptoms (LUTS) who have significant storage symptoms (urgency, frequency, nocturia). 1
When to Use Combination Therapy
Initiate combination therapy when:
- Men have moderate-to-severe LUTS with International Prostate Symptom Score (IPSS) ≥13 AND storage subscore ≥8 1
- Patients have failed to achieve adequate symptom control with alpha-blocker monotherapy 2
- Overactive bladder symptoms (urgency, frequency, nocturia) predominate alongside obstructive symptoms 1, 3
Efficacy Evidence
The combination demonstrates superior outcomes compared to tamsulosin alone:
- Significantly greater improvement in total IPSS at 8 weeks (P=0.03) and 12 weeks (P=0.006) 1
- Better storage symptom control and quality of life scores at all assessment points (P<0.01) 1
- Improved urinary frequency and work performance with combination therapy (P<0.001 for urinary symptoms) 3
- The benefit becomes more noticeable over time, with maximal effect by 21 days 4
Safety Profile and Monitoring
Key safety parameters to monitor:
Urinary Retention Risk
- Post-void residual (PVR) >300 mL occurred in 2.9% with combination vs 0.5% with tamsulosin alone (P=0.12, not statistically significant) 1
- Peak flow rates <5 mL/s occurred in 3.8% with combination vs 5.7% with tamsulosin alone (P=0.49) 1
- No increased risk of acute urinary retention was demonstrated in clinical trials, though patients were carefully selected 5
Patient Selection Criteria for Safe Combination Use
Only use combination therapy in men with:
- Maximum flow rate ≥8 mL/s with voided volume ≥125 mL 1
- Post-void residual volume ≤150 mL on two separate occasions 1
- No history of urinary retention 1
Drug Interactions and Contraindications
From the FDA label, tamsulosin should NOT be combined with:
Use tamsulosin with caution when combined with:
- PDE5 inhibitors (both are vasodilators; risk of symptomatic hypotension) 6
- Warfarin (inconclusive interaction data; monitor closely) 6
- Moderate CYP3A4 inhibitors (e.g., erythromycin) 6
Oxybutynin has no documented significant interaction with tamsulosin and co-administration does not affect the pharmacokinetics of either drug 1
Dosing Regimen
Standard combination protocol:
- Tamsulosin 0.4 mg once daily 1, 3
- Extended-release oxybutynin 10 mg once daily 1
- Duration: Minimum 12 weeks for full assessment of efficacy 1
Common Adverse Effects
Anticholinergic side effects from oxybutynin:
- Dry mouth (most common)
- Constipation
- Blurred vision 1
Alpha-blocker side effects from tamsulosin:
- Orthostatic hypotension and dizziness (counsel patients to avoid situations where syncope could cause injury) 6
- Retrograde ejaculation 6
- Intraoperative Floppy Iris Syndrome (advise patients to inform ophthalmologist before cataract/glaucoma surgery) 6
No significant increase in adverse events was reported with combination therapy compared to monotherapy in clinical trials 1, 3
Clinical Pitfalls to Avoid
Do not use this combination in:
- Men with PVR >150 mL at baseline 1
- Men with peak flow <8 mL/s 1
- Patients taking strong CYP3A4 inhibitors 6
- Patients with narrow-angle glaucoma (oxybutynin contraindication)
Screen for prostate cancer before initiating tamsulosin and at regular intervals, as BPH and prostate cancer frequently coexist 6
Gender-Specific Considerations
For ureteral stent-related symptoms: